Suspended animation fmt

Reading File

Asking for Preferences

Finding Sources

Searching PubMed

fecal microbiota transplantation AND suspended animation

Searching the Web

suspended animation FMT fecal microbiota transplant

Searching PubMed

fecal microbiota transplantation AND cryopreservation storage

Searching PubMed

gut microbiome AND therapeutic hypothermia OR cardiac arrest resuscitation

Searching the Web

FMT "suspended animation" OR "emergency preservation" microbiota transplant research 2024 2025

Reading Article

Finding Sources

Reading File

I now have enough to give a comprehensive answer. I'll interpret "suspended animation FMT" as the cryopreservation/long-term frozen storage of FMT products — the practice of putting microbial communities into a biologically inactive "suspended" state for banking and future use.

Fecal Microbiota Transplantation (FMT) in "Suspended Animation" — Frozen/Cryopreserved Storage

What It Means

"Suspended animation" in the FMT context refers to cryopreservation — freezing donor fecal material to halt microbial metabolism and preserve viability indefinitely, allowing stool banks to stockpile screened samples and deploy them on demand. This bypasses the logistical challenge of needing a fresh, same-day donor every time a patient requires treatment.

Why It Matters: The Logistics Problem

Fresh FMT requires a healthy, screened donor to produce a sample within hours of infusion. This creates real-world constraints:

Donor availability and compliance
Rapid processing time requirements
No ability to pre-screen for rare pathogens (e.g., ESBL-producing organisms) that take days to culture

Frozen biobanked FMT solves all three problems — Yamada's Textbook of Gastroenterology notes that "systematic screening of donors and distribution of frozen screened samples have been initiated, and currently at least 10,000 FMTs are performed in the US annually." — Yamada's Textbook of Gastroenterology, 7th ed.

Freezing Protocols

Standard cryopreservation of FMT involves:

Cryoprotectant addition (commonly 10% glycerol or DMSO) to prevent ice crystal formation
Storage at −80 °C (deep freeze), which is the benchmark temperature
Occasional −196 °C liquid nitrogen for ultra-long-term archiving
Thawing at refrigerator temperature (4 °C) or room temperature prior to use

Lyophilization (freeze-drying) is an alternative "suspended animation" approach — water is removed under vacuum, producing a powder that can be encapsulated in oral capsules and stored at −20 °C or even 2–8 °C.

Evidence for Long-Term Viability

Frozen at −80 °C

12-month ex vivo study (Soukupova et al., 2024 [PMID 38544348]): 15 samples from 9 donors stored at −80 °C with cryoprotectant showed no significant decrease in bacterial viability (aerobic or anaerobic) over 12 months (p = 0.09). Variability between donors exceeded variability within-donor over time — meaning the donor itself matters more than storage duration.

24-month clinical study (Facchin et al., 2025 [PMID 39672770]): Donor stools frozen for 2 years contained viable bacteria comparable to fresh samples. Despite some taxonomic shifts (Blautia producta and Bifidobacterium adolescentis increased post-thaw), clinical success rates were 71.4% at 1 year and 100% at end of follow-up for CDI — comparable to fresh FMT benchmarks.

Lyophilized Capsules

Lyophilization stability study (Zain et al., 2025 [PMID 40354906]): Freeze-dried encapsulated FMT retained species diversity through manufacturing and after 36 weeks at −80 °C. Crucially, capsules were also stable at −20 °C and 2–8 °C for 24 weeks with no significant loss of viable bacteria — enabling refrigerator-temperature distribution without cold chain requirements.

Taxonomic Changes During Frozen Storage

Not all bacteria survive equally:

Anaerobes are most vulnerable but show surprisingly minimal loss at −80 °C with cryoprotectant
Some taxa increase post-thaw (artifact of competitive release or differential recovery): Blautia producta, Bifidobacterium adolescentis, C. aerofaciens, Erysipelotrichaceae
Species richness dips when non-viable cells are excluded from analysis (seen with live/dead 16S sequencing)

The clinical implication: taxonomic composition changes slightly, but functional efficacy for CDI is preserved.

FDA-Approved Frozen Products

Two live biotherapeutic products (LBPs) derived from FMT research are now FDA-approved:

Vowst (fecal microbiota spores, live-brpk) — oral capsules, 2023
Rebyota (fecal microbiota, live-jslm) — rectal enema, 2022

A 2025 review in PMC notes that OpenBiome (the largest US stool bank supplying conventional frozen FMT) halted distribution of shipped frozen preparations on December 31, 2024, shifting the landscape toward these FDA-approved LBPs.

Key Safety Consideration for Frozen FMT

Frozen biobanking allows extensive pre-screening that fresh FMT cannot:

Stool cultures for ESBL/CRE organisms (takes 2–5 days)
PCR for viral pathogens (SARS-CoV-2, hepatitis E)
Parasite and toxin testing

However, the fatal ESBL E. coli transmission cases (2019, FDA safety alert) involved screened frozen capsules — highlighting that no screening protocol eliminates all risk. Immunocompromised recipients require particular caution. — Yamada's Textbook of Gastroenterology, 7th ed.

Summary Table

Parameter	Fresh FMT	Frozen (−80 °C)	Lyophilized Capsule
Shelf life	Hours	≥24 months	36 weeks (−80 °C); 24 weeks (2–8 °C)
Viability	Highest	Comparable at 12–24 months	Slightly reduced but clinically equivalent
Screening window	Limited	Full pathogen panel possible	Full pathogen panel possible
Cryoprotectant needed	No	Yes (glycerol/DMSO)	No (water removed)
Delivery route	Nasogastric/colonoscopic	Nasogastric/colonoscopic/enema	Oral capsule
CDI cure rate	~85–90%	~71–100% (studies vary)	Comparable

If you meant something different by "suspended animation FMT" — such as FMT in the context of emergency preservation/resuscitation research, or another meaning entirely — let me know and I'll redirect.

This is a shared conversation. Sign in to Orris to start your own chat.